Monitor and reassess affected pain and arthritis products, ensuring compliance with safety reporting protocols for products listed with known hidden ingredients.
Consumers should consult healthcare professionals if using this product and report any adverse effects to FDA’s MedWatch Safety Information.
Healthcare providers and manufacturers must now comply with new reporting obligations for adverse reactions associated with the use of Imaavy and ensure adherence to increased compliance requirements for its administration.
Regulatory intelligence teams should review ongoing studies and compliance with postmarketing requirements for the drugs listed, specifically focusing on their deadlines for completion and the nature of the studies required.
Stakeholders should incorporate the device authorization into labeling and signal management protocols to ensure compliance and effective communication regarding its capabilities.
Regulatory intelligence teams must update workflows to exclude clove oil as an anesthetic for fish and ensure compliance with the guidance, including awareness of approved alternatives.
Clinical investigations must now include justification for DDM selection and ensure that DHTs are verified and validated to support their intended clinical role.
Ensure compliance checks are reinforced in the inspection readiness processes to account for potential non-compliance surrounding product imports.
